Drug Profile

ARI 2243

Alternative Names: ARI-2243

Latest Information Update: 04 Apr 2016

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Arisaph Pharmaceuticals
Class Antihyperglycaemics; Small molecules
Mechanism of Action Dipeptidyl peptidase 4 inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

No development reported Type 2 diabetes mellitus

Most Recent Events

04 Apr 2016 No development reported - Phase-I for Type-2 diabetes mellitus (In volunteers) in USA (PO)
10 Jun 2008 Phase-I clinical trials in Type-2 diabetes mellitus in USA (PO)
10 Jun 2008 Preclinical pharmacodynamics data in Type-2 diabetes presented at the 68th Scientific Sessions of the American Diabetes Association (ADA-2008) ,

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com